Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-29T09:41:01.473Z Has data issue: false hasContentIssue false
  • English
  • Français

The rationale for and the current role of chemoradiotherapy

Published online by Cambridge University Press:  01 March 2007

R. J. Prestwich ,
D. Shakespeare  and
S. Waters
R. J. Prestwich*
Affiliation:
Leeds Cancer Centre, Cookridge Hospital, Hospital Lane, Leeds, UK
D. Shakespeare
Affiliation:
Leeds Cancer Centre, Cookridge Hospital, Hospital Lane, Leeds, UK
S. Waters
Affiliation:
Leeds Cancer Centre, Cookridge Hospital, Hospital Lane, Leeds, UK
*
Correspondance to: Robin James Prestwich MRCP, FRCR, JIF Building, Leeds Institute of Molecular Medicine, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK. E-mail: rprestwich@doctors.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Combined-modality treatment using chemotherapy and radiotherapy, particularly concurrently, has now become the standard of care for many solid tumour sites on the basis of improvements in locoregional disease control and in some cases survival. The rationale for combined-modality treatment, potential mechanisms of interaction, the therapeutic ratio and the current place of sequential and concurrent chemoradiotherapy are discussed.

Keywords

Chemotherapyradiotherapychemoradiotherapyinteractionrationale
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 6 , Issue 1 , March 2007 , pp. 11 - 19
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stupp, R, Mason, WP, van den Bent, MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005;352:987–996.CrossRefGoogle ScholarPubMed
Pignon, JP, Bourhis, J, Domenge, C, et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analysies of updated individual data. Lancet 2000;355:949–955.CrossRefGoogle Scholar
Herskovic, A, Martz, K, al-Sarraf, M, et al. Combined chemotherapy and radiotherapy compared with radiation alone in patients with cancer of the esophagus. N Eng J Med 1992;326:1593–1598.CrossRefGoogle ScholarPubMed
Pignon, JP, Arriagada, R, Idhe, D, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Eng J Med 1992;327:1618–1622.CrossRefGoogle ScholarPubMed
Stinchecombe, TE, Fried, D, Morris, DE, Socinskia, MA. Combined modality therapy for stage III non-small cell lung cancer. Oncologist 2006;11:809–823.CrossRefGoogle Scholar
Bossett, JF, Calcus, G, Mineur, L, et al. Pre-operative radiation in rectal cancer : effect and timing of additional chemotherapy 5-year results of the EORTC 22921 trial. J Clin Oncol 2005;23(Annual Meeting Proceedings: Abstract 3505).Google Scholar
Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-FU, and mitomycin. Lancet 1996;348:1049–1054.CrossRefGoogle Scholar
Green, JA, Kirwan, JM, Tierney, JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systemic review and metanalysis. Lancet 2001;358:781–786.CrossRefGoogle Scholar
Steele, GG. Terminology in the description of the drug-radiation interactions. Int J Radiat Oncol Biol Phys 1979;5:1145–1150.CrossRefGoogle Scholar
Wilson, GD, Bentzen, SM, Harari, PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006;16:2–9.CrossRefGoogle ScholarPubMed
Kinsella, TJ, Dobson, PP, Mitchell, JB, Farnace, AJ Jr. Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 1987;13:733–739.CrossRefGoogle ScholarPubMed
Curtis, SB. Lethal and potentially lethal lesions induced by radiation: a unified repair model. Radiat Res 1986;106:252–270.CrossRefGoogle ScholarPubMed
Goodhead, DT. Saturable repair models of radiation action in mammalian cells. Radiat Res 1985;104:S58–S67.CrossRefGoogle Scholar
Plunkett, W, Huang, P, Xu, PZ, Heineman, V, Grinewold, R, Gandhi, V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(Supp 11):3–10.Google ScholarPubMed
Gray, LH, Conger, AD, Ebert, M, Hornsey, S, Scott, OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638–648.CrossRefGoogle ScholarPubMed
Overgaard, J, Sand Hansen, H, Overgaard, M, et al. A randomised double-blind phase III study of nimorazole as a hypoxic radiosensitiser of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1998;46:135–146.CrossRefGoogle ScholarPubMed
Horsman, MR, Nordsmark, M, Overgaard, J. Techniques to assess the oxygenation of human tumours – state of the art. Strahlenther Onkol 1998;174(Suppl IV):2–5.Google ScholarPubMed
Horsman, MR, Chaplin, DJ, Overgaard, J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells. Cancer Res 1990;50:7430–7436.Google Scholar
Hermans, AF, Barendsen, GW. The proliferative status and clonogenic capacity of tumour cells in a transplantable rhabdomyosarcoma of the rat before and after irradiation with 800 rad of X-rays. Cell Tissue Kinet 1978;11:83–100.Google Scholar
Withers, HR, Taylor, JMG, Maciejewski, B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131–146.CrossRefGoogle ScholarPubMed
Milas, L, Fujii, T, Hunter, N, et al. Enhancement of tumour radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107–114.Google ScholarPubMed
Choy, H, Rodriquez, FF, Koester, S, Hilsenbed, S, van Hoff, DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71:3774–3778.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Emami, B, Lyman, J, Brown, A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–122.CrossRefGoogle ScholarPubMed
Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003;361:1927–1934.CrossRefGoogle Scholar
Adelstein, DJ, Leblanc, M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006;24:2624–2628.CrossRefGoogle ScholarPubMed
Tannock, IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14:3156–3174.CrossRefGoogle ScholarPubMed
Ma, BB, Bristow, RG, Kim, J, Siu, LL. Combined-modality treatment of solid tumours using radiotherapy and molecular targeted agents. J Clin Oncol 2003;21:2760–2776.CrossRefGoogle ScholarPubMed
Walker, MD, Alexander, E Jr, Hunt, WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333–343.CrossRefGoogle ScholarPubMed
Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Eng J Med 1991;324:1685–1690.CrossRefGoogle Scholar
Bernier, J, Domenge, C, Ozsahin, M, et al. Post operative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. EORTC 22931. N Eng J Med 2004;350:1945–1952.CrossRefGoogle ScholarPubMed
Forastiere, AA, Goepfert, H, Maor, M, et al. Concurrent chemotherapy and radiotherapy for organ preservation for organ preservation in advanced laryngeal cancer. N Eng J Med 2003;349:2091–2098.CrossRefGoogle ScholarPubMed
Al-Sarraf, M, LeBlanc, M, Shankar Giri, PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310–1317.CrossRefGoogle ScholarPubMed
Bonner, JA, Horari, PM, Giralt, J, et al. Radiotherapy plus cetuximab for Squamous cell carcinoma of the head and neck. New Eng J Med 2006;354:567–568.CrossRefGoogle ScholarPubMed
Bentzen, S, de Ruysscher, D, Wanders, S, et al. A novel time factor, the SER (start of any treatment and the end of radiotherapy), is predictive for local control and survival in a systematic overview of combined chest radiotherapy and chemotherapy for limited stage small cell lung cancer. Radiother Oncol 2004;73(Supp1):S143.Google Scholar
Takada, M, Fukuoka, M, Kawahara, M, Milisavljevic, S. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054–3060.CrossRefGoogle Scholar
Jeremic, B, Shibamoto, Y, Acimovic, L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: a randomised study. J Clin Oncol 1997;15:893–900.CrossRefGoogle Scholar
Turrisi, AT, Kim, K, Blum, R, et al. Twice daily compared to once-daily thoracic radiotherapy in limited-stage small cell lung cancer treated concurrently with Cisplatin and etoposide. N Eng J Med 1999;340:265–271.CrossRefGoogle Scholar
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.CrossRefGoogle Scholar
Furuse, K, Fukuoka, M, Kawaharam, et al. Phase III study of concurrent versus sequential thoracici radiotherapy in combination with mitomycin, vindsine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692–2699.CrossRefGoogle Scholar
Curran, D, Scott, C, Langer, C, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:2499a.Google Scholar
Zatloukal, P, Petruzelka, L, Zemanova, M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87–98.CrossRefGoogle ScholarPubMed
Fournel, P, Robinet, G, Thomas, P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francias de Pneumocancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–5917.CrossRefGoogle Scholar
Gerard, JP, Bonnetain, F, Conroy, T, Chapet, O, Bouche, O, Closon-Dejardin, MT, Untereiner, M, Leduc, B, Francois, E, Bedenne, L. Preoperative radiotherapy and 5-FU/folinic acid in T3-4 rectal cancers: results of the FFCD 9203 trial. J Clin Oncol 2005;23(Annual Meeting Proceedings:Abstract 3504).CrossRefGoogle Scholar
Sauer, R, Becker, H, Hohenberger, W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731–1740.CrossRefGoogle ScholarPubMed
Sebag-Montefiore, D. Developments in the use of chemoradiotherapy in rectal cancer. Colorectal Dis 2006;8(Supp 3):14–17.CrossRefGoogle ScholarPubMed
Nigro, ND, Vaitkevicius, VK, Considine, B Jr.Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354–356.CrossRefGoogle ScholarPubMed
Bartelink, H, Roelofsen, F, Eschwege, F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the EORTC Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040–2049.CrossRefGoogle Scholar
Flam, M, John, M, Pajak, TF, et al. Role of mitomycin in combination with 5-FU and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527–2539.CrossRefGoogle ScholarPubMed
Lukka, H, Hirte, H, Fyles, A, et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer – a metaanalysis. Clin Oncol 2002;14:203–212.CrossRefGoogle ScholarPubMed
Rodel, C, Grabenbauer, GG, Kuhn, R, et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: long term results. J Clin Oncol 2002;20:3061–3071.CrossRefGoogle ScholarPubMed
Jeter, MD, Janne, PA, Brooks, S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394–400.CrossRefGoogle ScholarPubMed
Kitani, H, Kosaka, T, Fujihara, T, et al. The ‘recall effect’ in radiotherapy: is subeffective, reparable damage involved? Int J Radiat Oncol Biol Phys 1990;18:689–695.CrossRefGoogle ScholarPubMed
Seymour, CB, Mothersill, C, Alper, T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol Relat Stud Phys Chem Med 1986;50:167–179.CrossRefGoogle ScholarPubMed